A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines

Abstract

Pharmaceutical compositions are disclosed for the treatment of acute, chronic and / or neuropathic pain. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsants, anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, and botulinum toxin. The method of using these compounds and a method of treating acute, chronic and / or neuropathic pain and migraine in a mammal including a human is also disclosed.

Description

Background of the invention [0001] The present invention relates to a pharmaceutical composition for the treatment of acute, chronic and / or neuropathic pain and migraine in mammals, such as humans, comprising a nicotinic receptor partial agonist (NRPA) and an analgesic including the class Opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), capsaicin receptors Agonists, narcotics, benzodiazepines, skeletal muscle relaxants, migraine treatments, anticonvulsants, antihypertensives, antiarrhythmics, antihistamines, steroids, caffeine, N-type calcium channel antagonists and botulinum toxin. The term NRPA refers to all compounds that bind at neuronal nicotinic acetylcholine specific receptor sites in mammalian tissues and elicit a partial agonist response. A partial agonist response is defined herein as a partial or incomplete functional effect in a given functi...

AI Technical Summary

Problems solved by technology

However, despite the therapeutic use of analgesics to treat pain, there is still a significant bias toward the use of analgesic compounds

Specifically, many of these compounds that have been tested in humans can cause serious side effects such as gastrointestinal complications, including nausea, vomiting, ulcers, and constipation, respiratory depression, and psychological and physical dependence